Moussa B. H. Youdim
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
Moussa B. H. Youdim is an Iranian/Israeli neuroscientist-neuropharmacologist who works on aminergic neurotransmitters metabolism and function and iron metabolism in brain function and dysfunction. He is co-developer with John Finberg of the anti-Parkinson drug, Azilect.
Birth and education
Moussa Youdim was born in Teheran, Iran in 1940 and is one of five children of Elihoo and Faranggis Youdim. From 1952 until 1959 he was educated at Aryeh House School (Brighton), Sherardwoods School (Welyn Garden City) and Borough Polytechnic, London in England. He completed his B.Sc. (1962), M. Sc.(1964) and Ph.D. in Biochemistry Department at McGill University and Allan Memorial Institute with Professor Theodore L Sourkes in 1966.
1966–1971. Post-doctoral fellow at thje University of London Post Graduate School, Queen Charlotte Maternity Hospital in Merton Sandler's laboratory.
1971. Department of Biochemistry Cambridge University in Prof. K.F. Tipton's laboratory.
1972. Wellcome Trust Fellow at College de France in Paris at Prof. Jacques Glowinski's laboratory.
1973–1977. Oxford University and MRC Unit of Clinical Pharmacology.
1977–1995. Technion Israel Institute of Technology Medical School, Professor and Chairman.
1991–1999. International Scholar in Residence at NIH Fogarty International Center for Advanced Study in Human Health Sciences, Bethesda, USA.
1997–2012. Directors of Eve Top Center of Excellence for Neurodegenerative Diseases Research and Teaching and USA national Parkinson Disease Center of Excellence Technion Medical School.
2006-2008 Distinguished Scientific Professor at Honk Kong Polytechnic University and Department of Anatomy Hong Kong University.
2008–2013. Distinguished Professor of Neurobiology at Yonsei World Class University Programme, Seoul, South Korea.
He holds Honorary Professorships at Armed Forces University Medical School in Bethesda, USA; and in China Janin University, Materia Medica Shanghai University of Chinese Traditional Medicine; Ruijin Medical school Shanghai and Qingdao University.
Youdim has served as consultant to Roche Pharmaceutical, TEVA, Ciba Geigy, Teva Pharmaceuticals Ltd and Continental Pharmaceutical. He is president and CSO of Youdim Pharmaceutical. He is a discoverer of the anti-Parkinson drugs selelgiline (l-deprenyl) and developer of monoamine oxidase B inhibitor rasagiline (Azilect), which was considered to be the first disease modifying drug used for Parkinson's disease and TVP 3326, ladostigil, for Alzheimer's disease. Experts have recently questioned whether rasagiline actually has significant disease modifying properties.
Honors and Awards
1974. Anna Monika International Prize, Switzerland.
1974. British Migraine Association Special Gold Medal.
1978. The Homayoon (Royal) Medal from the Shah, Iran.
1980. National Israel Psychobiology Institute Prize.
1986. Michael Landau Research Prize, Israel.
1990. Senator Burda International Prize for Parkinson's disease, Vienna, Austria.
1991. Claudius Galenus Gold Medal Prize Drug of the year l-Deprenyl (selegiline), Berlin, Germany.
1991. Deutscher Neuropharmakologie (AGNP) Prize, Nuremberg, Germany.
1991. Eli lilly Prize for Neuropharmacology, USA.
1993. The New England Prize doe Excellence in Science, Boston, USA.
1994 and 1977. Henning Andersen Prize, Sweden.
1997. "Honoris Causa" Honorary Doctor of Philosophy, Semmelweiss University Medical School, Hungary.
1998. "Honoris Causa" Honorary Doctor Of Philosophy University of Pisa and Ecole Superior Nationale, Italy.
2006. Henry Taub Prize for Excellence in Research, Technion.
2006. Nathan Shock Lecture, NIH Institute of Ageing, Bethesda, USA.
2007. Melvin Yahr Lecture, Mount Sinai School of Medicine, USA.
2007. World Federation of Neurology 17th International Congress of Parkinson's disease Award for Contribution to Parkinson's disease, Netherland.
2008. Thomas Schkeler Lecture, Ohio State University, USA.
2009. Shanghai Baiyulan Award, Ruijin Medical School. Shanghai, China.
2010. Elected Member of Leopoldina German Academy of Sciences.
2011. Theodore l. Sourkes lecture, Parkinson's disease, McGill University, Canada.
2011. European College of Neuropsychopharmacology (ECNP) Life Time Achievement Prize in Neuropsychopharmacology, Netherland.
2011. EMET Prize for Brain Science, Israel.
2012. Giant Pioneer of Catecholamine Research Prize, 11th International Catecholmaine Congress, USA.
2012. CINP (International College of Neuropsyhcopharmacology) Pioneering Neuropsychopharmacology Prize, with Arvid Carlsson Medal, Sweden.
2013. Elected Honorary Member of Israel Neuroscience Society.
- Youdim MB, Bakhle YS.(2006) "Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness". Br J Pharmacol. 147 Suppl 1:S287-96.
- Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR.(2004) "Iron, brain aging and neurodegenerative disorders". Nat Rev Neurosci. 5(11):863-73.
- Youdim MB, Edmondson D, Tipton KF.(2006) "The therapeutic potential of monoamine oxidase inhibitors". Nat Rev Neurosci. 7(4):295-309.
- Weinreb O, Amit T, Mandel S, Kupershmidt L, Youdim MB.(2010) "Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities". Antioxid Redox Signal. 13(6):919-49.
- Youdim, M.B. (November 2003). "Rasagiline: an anti-Parkinson drug with neuroprotective activity". Expert Review of Neurotherapeutics. 3 (6): 737–49. doi:10.1586/1473718.104.22.1687. PMID 19810877. S2CID 23857497.
- Naoi, M.; Maruyama, W.; Youdim, M.B.; Yu, P.; Boulton, A.A. (2003). "Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase". Inflammopharmacology. 11 (2): 175–81. doi:10.1163/156856003765764344. PMID 15035819. S2CID 60465.
- Young, Donna. "Panel: Teva's Azilect Data Close, but No Cigar for Parkinson's Delay Claim". michaeljfox.org. FoxFeed Blog. Retrieved 21 February 2016.